Enerzair Breezhaler - first medicinal product with fixed-dose inhalation three-drug combination for asthma treatment
Abstract
Recently, in July 2020, the European Medicines Agency approved the first ever medicinal product containing a fixed triple combination in the inhalation system to treat asthma. Enerzair Breezhaler contains a fixed dose combination of three active substances (indacaterol / glycopyrronium / mometasone furoate) in capsule form, which are given using an inhaler.
Enerzair Breezhaler is indicated for the maintenance treatment of asthma in adult patients who are not adequately controlled on a maintenance combination of a long-acting β2 agonist and a high dose of inhaled corticosteroid and have experienced one or more asthma exacerbations in the previous year. The product is intended for the treatment of more severe asthmatics.
Inhalation once daily may have a positive effect on patients' adherence to treatment. According to current studies, the combination of drug molecules in the product appears to be a promising approach in the asthma treatment portfolio.